{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:50:46Z","timestamp":1784307046812,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005075","name":"Universitair Medisch Centrum Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.schres.2018.01.016","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T22:48:22Z","timestamp":1517525302000},"page":"281-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Towards a comprehensive routine outcome monitoring program for people with psychotic disorders: The Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS)"],"prefix":"10.1016","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6731-7836","authenticated-orcid":false,"given":"Agna A.","family":"Bartels-Velthuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Arends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerdina H.M.","family":"Pijnenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lex","family":"Wunderink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1720-1231","authenticated-orcid":false,"given":"Frederike","family":"J\u00f6rg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Veling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith J.","family":"Liemburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stynke","family":"Castelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henderikus","family":"Knegtering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bruggeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2018.01.016_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th edition","author":"American Psychiatric Association","year":"2000"},{"issue":"3","key":"10.1016\/j.schres.2018.01.016_bb0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2018.01.016_bb0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2975\/27.2004.375.391","article-title":"Skills training for people with severe mental illness","volume":"27","author":"Bellack","year":"2004","journal-title":"Psychiatr. Rehabil. J."},{"issue":"4","key":"10.1016\/j.schres.2018.01.016_bb0020","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/0269881116631652","article-title":"Cannabis use in people with severe mental illness: the association with physical and mental health--a cohort study. A Pharmacotherapy Monitoring and Outcome Survey study","volume":"30","author":"Bruins","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2018.01.016_bb0025","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16m10831","article-title":"Persistent low rates of treatment of metabolic risk factors in people with psychotic disorders: a PHAMOUS study","author":"Bruins","year":"2017","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2018.01.016_bb0030","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0447.2008.01216.x","article-title":"The effectiveness of peer support groups in psychosis: a randomized controlled trial","volume":"118","author":"Castelein","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2018.01.016_bb0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"De Hert","year":"2009","journal-title":"World Psychiatry."},{"issue":"2","key":"10.1016\/j.schres.2018.01.016_bb0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/j.2051-5545.2011.tb00036.x","article-title":"Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry."},{"issue":"2\u20133","key":"10.1016\/j.schres.2018.01.016_bb0045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.schres.2005.02.010","article-title":"A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors","volume":"76","author":"de Leon","year":"2005","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2018.01.016_bb0050","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/09540261.2015.1045408","article-title":"Routine outcome measurement in the Netherlands - a focus on benchmarking","volume":"27","author":"Delespaul","year":"2015","journal-title":"Int. Rev. Psychiatr."},{"key":"10.1016\/j.schres.2018.01.016_bb0055","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1192\/bjp.177.6.511","article-title":"Causes and consequences of duration of untreated psychosis in schizophrenia","volume":"177","author":"Drake","year":"2000","journal-title":"Br. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2018.01.016_bb0060","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/0004867412453089","article-title":"Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis","volume":"46","author":"Galletly","year":"2012","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2018.01.016_bb0065","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. Psychiatry"},{"issue":"17","key":"10.1016\/j.schres.2018.01.016_bb0070","first-page":"E285","article-title":"Diagnosis and management of the metabolic syndrome - an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement - executive summary","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.schres.2018.01.016_bb0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1440-1614.2000.00685.x","article-title":"Cannabis use and psychosis: a review of clinical and epidemiological evidence","volume":"34","author":"Hall","year":"2000","journal-title":"Aust. N. Z. J. Psychiatry."},{"issue":"3","key":"10.1016\/j.schres.2018.01.016_bb0080","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11892-010-0112-8","article-title":"Metabolic syndrome associated with schizophrenia and atypical antipsychotics","volume":"10","author":"Hasnain","year":"2010","journal-title":"Curr. Diab. Rep."},{"issue":"2","key":"10.1016\/j.schres.2018.01.016_bb0085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2018.01.016_bb0090","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/schbul\/sbn177","article-title":"Psychosocial treatments to promote functional recovery in schizophrenia","volume":"35","author":"Kern","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2018.01.016_bb0095","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jad.2011.10.014","article-title":"A systematic review of instruments to measure depressive symptoms in patients with schizophrenia","volume":"140","author":"Lako","year":"2012","journal-title":"J. Affect. Disord."},{"issue":"4","key":"10.1016\/j.schres.2018.01.016_bb0100","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eurpsy.2010.10.007","article-title":"The course of depressive symptoms and prescribing patterns of antidepressants in schizophrenia in a one-year follow-up study","volume":"27","author":"Lako","year":"2012","journal-title":"Eur. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2018.01.016_bb0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.schres.2013.02.027","article-title":"A brief version of the subjects' response to antipsychotics questionnaire to evaluate treatment effects","volume":"147","author":"Lako","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.01.016_bb0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.psychres.2016.01.009","article-title":"Altered emotional experiences attributed to antipsychotic medications - a potential link with estimated dopamine D2 receptor occupancy","volume":"236","author":"Lako","year":"2016","journal-title":"Psychiatry Res."},{"issue":"11","key":"10.1016\/j.schres.2018.01.016_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113521","article-title":"The psychosis recent onset GRoningen survey (PROGR-S): defining dimensions and improving outcomes in early psychosis","volume":"9","author":"Liemburg","year":"2014","journal-title":"PLoS One"},{"issue":"293","key":"10.1016\/j.schres.2018.01.016_bb0120","article-title":"Changing the obesogenic environment of severe mentally ill residential patients: ELIPS, a cluster randomised study design","volume":"14","author":"Looijmans","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2018.01.016_bb0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2018.01.016_bb0130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1037\/prj0000061","article-title":"Effectiveness of individual placement and support for people with severe mental illness in The Netherlands: a 30-month randomized controlled trial","volume":"37","author":"Michon","year":"2014","journal-title":"Psychiatr. Rehabil. J."},{"issue":"2","key":"10.1016\/j.schres.2018.01.016_bb0135","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"8","key":"10.1016\/j.schres.2018.01.016_bb0140","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/j.1440-1614.2005.01656.x","article-title":"Assessing reliable and clinically significant change on health of the nation outcome scales: method for displaying longitudinal data","volume":"39","author":"Parabiaghi","year":"2005","journal-title":"Aust. N. Z. J. Psychiatry."},{"issue":"1\u20133","key":"10.1016\/j.schres.2018.01.016_bb0145","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.schres.2007.12.468","article-title":"Adjunctive psychosocial therapies for the treatment of schizophrenia","volume":"100","author":"Patterson","year":"2008","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2018.01.016_bb0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0447.1992.tb01456.x","article-title":"Influence of cannabis abuse on schizophrenic psychopathology","volume":"85","author":"Peralta","year":"1992","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2018.01.016_bb0155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/002076409904500102","article-title":"Application and results of the Manchester short assessment of quality of life (MANSA)","volume":"45","author":"Priebe","year":"1999","journal-title":"Int. J. Soc. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2018.01.016_bb0160","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3923\/ijp.2010.796.807","article-title":"Cannabis use and mental health: a review of recent epidemiological research","volume":"6","author":"Richardson","year":"2010","journal-title":"Int. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.schres.2018.01.016_bb0170","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/JCP.0b013e3181fbfac4","article-title":"Association between the 1291-C\/G polymorphism in the adrenergic alpha-2a receptor and the metabolic syndrome","volume":"30","author":"Risselada","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"62","key":"10.1016\/j.schres.2018.01.016_bb9000","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/tpj.2010.66","article-title":"Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: A replication study","volume":"12","author":"Risselada","year":"2012","journal-title":"The Pharmacogenomics Journal"},{"issue":"3","key":"10.1016\/j.schres.2018.01.016_bb0175","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0447.2008.01232.x","article-title":"A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole","volume":"118","author":"Schorr","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"issue":"13","key":"10.1016\/j.schres.2018.01.016_bb0180","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jpsychires.2009.03.002","article-title":"The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year","volume":"43","author":"Schorr","year":"2009","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2018.01.016_bb0185","author":"Statistics Netherlands"},{"issue":"2","key":"10.1016\/j.schres.2018.01.016_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149785","article-title":"Confirmatory factor analysis and differential relationships of the two subdomains of negative symptoms in chronically ill psychotic patients","volume":"11","author":"Stiekema","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.schres.2018.01.016_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-016-0817-6","article-title":"Do routine outcome monitoring results translate to clinical practice? A cross-sectional study in patients with a psychotic disorder","volume":"16","author":"Tasma","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2018.01.016_bb0200","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2196\/jmir.2851","article-title":"A web-based tool to support shared decision making for people with a psychotic disorder: randomized controlled trial and process evaluation","volume":"15","author":"van der Krieke","year":"2013","journal-title":"J. Med. Internet Res."},{"issue":"2","key":"10.1016\/j.schres.2018.01.016_bb0205","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1017\/S0033291708003814","article-title":"A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder","volume":"39","author":"van Os","year":"2009","journal-title":"Psychol. Med."},{"issue":"3","key":"10.1016\/j.schres.2018.01.016_bb0210","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.psychres.2010.03.011","article-title":"Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia","volume":"177","author":"Vancampfort","year":"2010","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.schres.2018.01.016_bb0215","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/YPG.0b013e3283458a51","article-title":"Association between the ROBO1 gene and body mass index in patients using antipsychotics","volume":"21","author":"Vehof","year":"2011","journal-title":"Psychiatr. Genet."},{"issue":"2","key":"10.1016\/j.schres.2018.01.016_bb0220","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00213-011-2211-x","article-title":"Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication","volume":"216","author":"Vehof","year":"2011","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.schres.2018.01.016_bb0225","first-page":"395","article-title":"Functional remission of people with serious mental illness (SMI): psychometric properties of a new ROM-instrument","volume":"57","author":"Wiersma","year":"2015","journal-title":"Tijdschr. Psychiatr."},{"key":"10.1016\/j.schres.2018.01.016_bb0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1192\/bjp.172.1.11","article-title":"Health of the nation outcome scales (HoNOS) - Research and development","volume":"172","author":"Wing","year":"1998","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2018.01.016_bb0235","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.yic.0000185023.55903.ba","article-title":"Evaluation of the subjects' response to antipsychotics questionnaire","volume":"21","author":"Wolters","year":"2006","journal-title":"Int. Clin. Psychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418300367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418300367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T18:50:16Z","timestamp":1720205416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996418300367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":47,"alternative-id":["S0920996418300367"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2018.01.016","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards a comprehensive routine outcome monitoring program for people with psychotic disorders: The Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS)","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2018.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}